You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中威電子(300270.SZ)與NuraLogix Corporation簽訂補充協議 公司目前正佈局的深度AI產品-情感識別產品
格隆匯 11-04 16:57

格隆匯11月4日丨中威電子(300270.SZ)公佈,誠如之前公告披露,20181023日,公司(“甲方”)與Nuralogix Corporation(“紐洛斯”)、杭州紐洛斯人工智能有限公司(是NuraLogix Corporation在中國設立的全資子公司,“杭州紐洛斯”,與NuraLogix Corporation統稱“乙方”)簽訂了《合作框架協議》,雙方就TOI血譜光學成像技術和DeepAffex情感人工智能技術在安防領域的應用項目的研究和開發達成長期合作意向。

2019113日,公司與Nuralogix Corporation、杭州紐洛斯人工智能有限公司在2018年雙方簽訂的合作框架協議基礎上,就TOI血譜光學成像技術和DeepAffex情感人工智能技術基礎上開發的情感AI攝像機、非接觸式生理心理多導儀和測謊系統進行深化合作簽訂了《合作框架協議之補充協議

合作安排如下:(1)在遵循本補充協議條款和條件的條件下(包但不限於本第2條所述條件),乙方授予甲方使用TOI血譜光學成像與DeepAffex情感人工智能技術在中國大陸(不含香港、澳門和台灣)從事下述活動的獨家授權(i) 進行情感AI攝像機的研發、生產銷售;(ii) 進行非接觸式生理心理多導儀的研發、生產和銷售;和(iii) 公共安全行業(包括公安、檢察院、司法、紀檢單位等)研發、生產、銷售測謊系統。上述授權不可轉讓和分授權。

(2)上述授權期對每個產品均為2每個產品授權期自乙方正式發佈並向甲方提供與該產品對應的、經乙方正式書面確認已經滿符合甲方所需功能的【TOI血譜光學成像技術和/DeepAffex™情感人工智能技術】之日開始起算。乙方承諾就每一產品自協議簽訂之日起,至乙方正式發佈和向甲方提供本補充協議中該產品對應的【TOI血譜光學成像技術和DeepAffex情感人工智能技術】之日,向甲方提供不超過【12】個月的保護期。在上述保護期內,乙方不得向第三方提供就本協議所述情感AI攝像機、非接觸式生理心理多導儀和測謊系統的授權。如果乙方未能在協議簽訂之日起【12個月之內正式發佈和向甲方提供相應的【TOI血譜光學成像技術和DeepAffex™情感人工智能技術】,除非雙方均書面同意乙方可延長開發期之外,本協議應可由乙方解除。

(3)雙方同意在實現雙方預期的商業目標的基礎上乙方將優先考慮與甲方持續開展深入合作

次協議的簽署是在2018年雙方簽訂的合作框架協議基礎上,基於TOI血譜光學成像技術和DeepAffex情感人工智能技術基礎上開發的情感AI攝像機非接觸式生理心理多導儀和測謊系統進行深化合作簽訂協議簽署後,公司將享有紐洛斯授予的使用其TOI血譜光學成像與DeepAffex情感人工智能技術在中國大陸(不含香港、澳門和台灣)從事下述活動的獨家授權(i) 進行情感AI攝像機的研發、生產銷售;(ii) 進行非接觸式生理心理多導儀的研發、生產和銷售;和(iii) 公共安全行業(包括公安、檢察院、司法、紀檢單位等)研發、生產、銷售測謊系統。

公司目前正在佈局的深度AI產品-情感識別產品,是基於血譜光學成像技術的情感人工智能技術,可以通過攝像機遠程非接觸檢測多項人體生理、心理指標,並形成了場景性情感分析和公共安全情感分析兩大產品業務方向,2019 年我們優先佈局於高校學生心理健康領域,服務社會與教育部門對學生心理健康的關注,目前已與多所專業心理健康研究高校建立聯繫。此次獨家授權協議簽署後,將為後續雙方在國內公共安全行業(包括公安、檢察院、司法、紀檢單位等)市場佈局打下堅實的基礎,將加強公司的可持續發展能力,推動公司未來業務的發展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account